RYE, N.Y., Sept. 8, 2011 /PRNewswire/ — Curemark LLC, a
drug research and development company focused on the treatment of
neurological diseases, announced today that it was issued Patent
8,012,710: Methods of treating and diagnosing Parkinson’s
disease and related dysautonomic disorders.  The patent
covers Curemark’s biomarker as applied to diagnosing an individual
with Parkinson’s disease, as well as determining if an individual
has a likelihood to develop Parkinson’s disease.

Parkinson’s disease is a degenerative neurological disorder that
affects one million individuals in the United States and more than
five million worldwide.  Curemark’s patent also includes the
diagnosis of specific other dysautonomic conditions including
Familial Dysautonomia (FD), Diabetic autonomic failure, and
Orthostatic Intolerance.

“Curemark’s technology, especially as applied to Parkinson’s,
represents one of the first novel patented biomarkers for
Parkinson’s disease,” states Matthew Heil, PhD, Sr. Vice President
of Research and Development at Curemark. “This biomarker, which
indicates enzyme deficiencies, can be used to diagnose the disease
and also can be utilized as an early screening tool to identify
those who may have the propensity to develop Parkinson’s
disease.”

Dr. Joan Fallon, CEO of Curemark states, “This patent represents
a further advancement of our breakthrough platform technology.
 We hope that the diagnosis of Parkinson’s and other
dysautonomias through the use of our biomarker could potentially
help not only with early diagnosis, but also with the development
of treatments to mitigate the symptoms of Parkinson’s disease and
other dysautonomias.”

About CUREMARK LLC

Curemark is a drug research and development company focused on
the treatment of neurological and other diseases, especially those
with dysautonomic components, by addressing certain key
gastrointestin

‘/>”/>

SOURCE